

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Estimated average burden  
 hours per response: 0.5

☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Hyllengren Eric J</u> <hr/> (Last) (First) (Middle) <u>C/O ATARA BIOTHERAPEUTICS, INC.</u> <u>1280 RANCHO CONEJO BOULEVARD</u> <hr/> (Street) <u>THOUSAND</u> <u>CA</u> <u>91320</u> <u>OAKS</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Atara Biotherapeutics, Inc. [ ATRA ]</u> <hr/> 3. Date of Earliest Transaction (Month/Day/Year) <u>03/31/2025</u> <hr/> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <u>X</u> Other (specify below) <u>Former EVP, CFO &amp; COO</u> <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <u>X</u> Form filed by One Reporting Person Form filed by More than One Reporting Person
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)		Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$996.25	03/31/2025		D		1,900 08/20/2022 09/03/2025	Common Stock 1,900	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$961.75	03/31/2025		D		460 02/06/2023 02/05/2029	Common Stock 460	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$303.75	03/31/2025		D		496 04/01/2023 02/28/2030	Common Stock 496	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$303.75	03/31/2025		D		154 (1) 02/28/2030	Common Stock 154	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$427.63	03/31/2025		D		381 04/01/2023 02/28/2031	Common Stock 381	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$427.63	03/31/2025		D		350 (2) 02/28/2031	Common Stock 350	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$255.25	03/31/2025		D		262 04/01/2023 02/29/2032	Common Stock 262	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$255.25	03/31/2025		D		543 (3) 02/29/2032	Common Stock 543	\$0 <sup>(4)</sup>	160	D	
Employee Stock Option (Right to Buy)	\$97.75	03/31/2025		D		331 04/01/2023 02/28/2033	Common Stock 331	\$0 <sup>(4)</sup>	0	D	
Employee Stock Option (Right to Buy)	\$97.75	03/31/2025		D		8,961 (3) 02/28/2033	Common Stock 8,961	\$0 <sup>(4)</sup>	2,656	D	

## Explanation of Responses:

1. 1/11th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following ten (10) months, subject to the reporting person's continuous service.

2. 1/23rd of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following twenty-two (22) months, subject to the reporting person's continuous service.
3. 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service.
4. This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of \$100 as consideration.

/s/ John Chao, Attorney-in-Fact for  
Eric J. Hyllengren

04/02/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**